Evidence map›Paper›PMID 34648110›Full record

ArticleJournal, genetic engineering & biotechnology2021

Expression of acid cleavable Asp-Pro linked multimeric AFP peptide in E. coli.

Murad Mollaev, Artur Zabolotskii, Neonila Gorokhovets, Elena Nikolskaya, Maria Sokol, Andrey Tsedilin, Mariia Mollaeva, Margarita Chirkina, Timofey Kuvaev, Anna Pshenichnikova and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Journal, genetic engineering & biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Synergetic Enhancement of Tumor Double-Targeted MRI Nano-Probe.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Murad MollaevBiotechnology and Industrial Pharmacy Department, Lomonosov Institute of Fine Chemical Technologies, MIREA - Russian Technological University, 86 Vernadsky avenue, Moscow, 119454, Russia.
Artur ZabolotskiiJSC Russian Research Center for Molecular Diagnostics and Therapy, 8 Simferopolsky boulevard, Moscow, 117638, Russia.
Neonila GorokhovetsI.M. Sechenov First Moscow State Medical University, 8-2 Trubetskaya street, Moscow, 119991, Russia.
Elena NikolskayaJSC Russian Research Center for Molecular Diagnostics and Therapy, 8 Simferopolsky boulevard, Moscow, 117638, Russia.
Maria SokolJSC Russian Research Center for Molecular Diagnostics and Therapy, 8 Simferopolsky boulevard, Moscow, 117638, Russia.
Andrey TsedilinFundamentals of Biotechnology Federal Research Center, RAS, 33 Leninsky avenue, Moscow, 119071, Russia.
Mariia MollaevaJSC Russian Research Center for Molecular Diagnostics and Therapy, 8 Simferopolsky boulevard, Moscow, 117638, Russia.
Margarita ChirkinaJSC Russian Research Center for Molecular Diagnostics and Therapy, 8 Simferopolsky boulevard, Moscow, 117638, Russia.
Timofey KuvaevNational Research Center "Kurchatov Institute", Research Institute for Genetics and Selection of Industrial Microorganisms, 1 1-Y Dorozhnyy Proyezd, Moscow, 117545, Russia.
Anna PshenichnikovaBiotechnology and Industrial Pharmacy Department, Lomonosov Institute of Fine Chemical Technologies, MIREA - Russian Technological University, 86 Vernadsky avenue, Moscow, 119454, Russia.
Nikita YabbarovJSC Russian Research Center for Molecular Diagnostics and Therapy, 8 Simferopolsky boulevard, Moscow, 117638, Russia. marvint@inbox.ru.ORCID http://orcid.org/0000-0003-3361-9136
Russian Research Center for Molecular Diagnostics and Therapy · RUMoscow State University of Fine Chemical Technologies · RUFederal Research Centre «Fundamentals of Biotechnology» of the Russian Academy of Sciences · RUKurchatov Institute · RULomonosov Moscow State University · RUSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDifficult to express peptides are usually produced by co-expression with fusion partners. In this case, a significant mass part of the recombinant product falls on the subsequently removed fusion partner. On the other hand, multimerization of peptides is known to improve its proteolytic stability in E. coli due to the inclusion of body formation, which is sequence specific. Thereby, the peptide itself may serve as a fusion partner and one may produce more than one mole of the desired product per mole of fusion protein. This paper proposes a method for multimeric production of a human alpha-fetoprotein fragment with optimized multimer design and processing. This fragment may further find its application in the cytotoxic drug delivery field or as an inhibitor of endogenous alpha-fetoprotein.

resultsMultimerization of the extended alpha-fetoprotein receptor-binding peptide improved its stability in E. coli, and pentamer was found to be the largest stable with the highest expression level. As high as 10 aspartate-proline bonds used to separate peptide repeats were easily hydrolyzed in optimized formic acid-based conditions with 100% multimer conversion. The major product was represented by unaltered functional alpha-fetoprotein fragment while most side-products were its formyl-Pro, formyl-Tyr, and formyl-Lys derivatives. Single-step semi-preparative RP-HPLC was enough to separate unaltered peptide from the hydrolysis mixture.

conclusionsA recombinant peptide derived from human alpha-fetoprotein can be produced via multimerization with subsequent formic acid hydrolysis and RP-HPLC purification. The reported procedure is characterized by the lower reagent cost in comparison with enzymatic hydrolysis of peptide fusions and solid-phase synthesis. This method may be adopted for different peptide expression, especially with low amino and hydroxy side chain content.

Indexed as

Alpha-fetoproteinAsp-Pro cleavageMultimer expressionRecombinant peptide

Identifiers

PMID34648110
PMCPMC8517049
OpenAlexW3206911417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.